SAB Biotherapeutics, Inc.
Develops human polyclonal antibodies for autoimmune disorders and infectious diseases.
SABS | NDAQ
Overview
Corporate Details
- ISIN(s):
- US0891152086 (+2 more)
- LEI:
- Country:
- United States of America
- Address:
- 777 W 41ST ST, 33140 MIAMI BEACH
- Website:
- https://www.sab.bio/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
SAB Biotherapeutics, Inc. (SAB BIO) is a clinical-stage biopharmaceutical company that develops novel immunotherapies to treat and prevent immune and autoimmune disorders. The company's unique platform produces fully human, multi-targeted, high-potency polyclonal antibodies without requiring human donors. Its lead asset, SAB-142, is a disease-modifying therapy designed to delay the progression of Type 1 Diabetes (T1D) by addressing its underlying autoimmune cause. SAB BIO's pipeline also includes programs targeting infectious diseases such as influenza and C. difficile.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all SAB Biotherapeutics, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for SAB Biotherapeutics, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for SAB Biotherapeutics, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
